A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Optimal Health Research

Status and phase: Completed; Phase 2

Conditions: Breast Cancer; Lung Cancer; Prostate Cancer

Treatments: Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).; Dietary Supplement: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell); Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05137067

RPC006

Details and patient eligibility

About

This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.

Full description

This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients. The study will be observing the standard treatment protocol for any degradation or enhancement due to the nutraceutical.

Enrollment: 90 patients

Sex: All

Ages: 25 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Active breast cancer patients taking one of the studies listed drugs within the age range.

Active lung cancer patients taking one of the studies listed drugs within the age range.

Active prostate cancer patients taking one of the studies listed drugs within the age range.

Exclusion criteria

Anyone without the three types of cancer (breast cancer, lung cancer, prostate cancer) listed in inclusion criteria.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

90 participants in 9 patient groups, including a placebo group

Chemotherapeutic agent A (Docetaxel)

Other group

Description:

The patients with breast cancer will receive chemotherapeutic agent A

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Chemotherapeutic agent A (Docetaxel) plus placebo

Placebo Comparator group

Description:

The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Chemotherapeutic agent A (Docetaxel) plus RaproCell

Active Comparator group

Description:

The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.

Treatment:

Dietary Supplement: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)

Chemotherapeutic agent B (Cisplatin)

Other group

Description:

The patients with lung cancer will receive Chemotherapeutic agent B

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Chemotherapeutic agent B (Cisplatin) plus placebo

Placebo Comparator group

Description:

The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Chemotherapeutic agent B (Cisplatin) plus RaproCell

Active Comparator group

Description:

The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.

Treatment:

Dietary Supplement: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)

Chemotherapeutic agent C (Docetaxel)

Other group

Description:

The patients with prostate cancer will receive Chemotherapeutic agent C

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Chemotherapeutic agent C (Docetaxel) plus placebo

Placebo Comparator group

Description:

The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.

Treatment:

Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Chemotherapeutic agent C plus (Docetaxel) RaproCell

Active Comparator group

Description:

The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.

Treatment:

Dietary Supplement: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)